ProCE Banner Activity

TOURMALINE-MM1: Improved PFS With Ixazomib + Len/Dex in R/R MM

Slideset Download
Conference Coverage
Newly FDA approved ixazomib combination therapy with lenalidomide/dexamethasone prolongs PFS and increases response rate in patients with R/R MM.

Released: December 11, 2015

Expiration: December 09, 2016

Share

Provided by

Jointly provided by the Annenberg Center for Health Sciences at Eisenhower and Clinical Care Options, LLC
ProCE Banner

Supporters

Amgen, Inc.

Celgene

Incyte

Merck & Co., Inc.

Millennium Takeda

Seagen